Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32913273&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain #MMPMID32913273
Chi X; Liu X; Wang C; Zhang X; Li X; Hou J; Ren L; Jin Q; Wang J; Yang W
Nat Commun 2020[Sep]; 11 (1): 4528 PMID32913273show ga
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide efficient blockade for viral infection and are a promising category of biological therapies. Here, using SARS-CoV-2 spike receptor-binding domain (RBD) as a bait, we generate a panel of humanized single domain antibodies (sdAbs) from a synthetic library. These sdAbs reveal binding kinetics with the equilibrium dissociation constant (K(D)) of 0.99-35.5 nM. The monomeric sdAbs show half maximal neutralization concentration (EC(50)) of 0.0009-0.07 microg/mL and 0.13-0.51 microg/mL against SARS-CoV-2 pseudotypes, and authentic SARS-CoV-2, respectively. Competitive ligand-binding experiments suggest that the sdAbs either completely block or significantly inhibit the association between SARS-CoV-2 RBD and viral entry receptor ACE2. Fusion of the human IgG1 Fc to sdAbs improve their neutralization activity by up to ten times. These results support neutralizing sdAbs as a potential alternative for antiviral therapies.
free
free
free
Nat+Commun 2020 ; 11 (1): 4528
